Real-world baseline treatment patterns and overall survival (rwOS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in the United States.

被引：0
|
作者：
Kariburyo-Yay, Furaha
George, Daniel J.
Aggarwal, Himani
Tepsick, Jon G.
Yu, Rebekah
Li, Weiyan
Orji, Chinelo
Lal, Lincy S.
Ghate, Sameer R.
机构：
[1] ConcertAI LLC, Cambridge, MA USA
[2] Duke Univ, Inst Canc, Durham, NC USA
[3] Merck & Co Inc, Rahway, NJ USA
[4] AstraZeneca, Gaithersburg, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5054
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Real-world genetic testing patterns in metastatic castration-resistant prostate cancer
    Shore, Neal
    Ionescu-Ittu, Raluca
    Yang, Lingfeng
    Laliberte, Francois
    Mahendran, Malena
    Lejeune, Dominique
    Yu, Louise
    Burgents, Joseph
    Duh, Mei Sheng
    Ghate, Sameer R.
    FUTURE ONCOLOGY, 2021, 17 (22) : 2907 - 2921
  • [32] Real-world evidence (RWE) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ): Comparison with the randomized clinical study CARD
    de Wit, R.
    Freedland, S.
    Oudard, S.
    Marinov, G.
    Capart, P.
    Combest, A.
    Peterson, R.
    Ozatilgan, A.
    Morgans, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S518 - S518
  • [33] Treatment patterns and survival in men with metastatic castration-resistant prostate cancer (mCRPC): A systematic literature review of 35 real-world observational studies.
    Raval, Amit D.
    Queen, V. Viji
    Korn, Matthew J.
    Quintero, Vanessa
    Freedland, Stephen J.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [34] Real-world treatment patterns in French metastatic castration-resistant prostate cancer patients under abiraterone or enzalutamide
    Scailteux, L. M.
    Vincendeau, S.
    Gravis, G.
    Mathieu, R.
    Balusson, F.
    Kerbrat, S.
    Oger, E.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 : 10 - 11
  • [35] Real-world use of bone-modifying agents (BMA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the US.
    Swami, Umang
    Jo, Yeonjung
    Hage Chehade, Chadi
    Ozay, Zeynep Irem
    Sayegh, Nicolas
    Gebrael, Georges
    Ostrowski, Micah
    Campbell, Patrick
    Hu, Siqi
    Fortuna, Gliceida M. Galarza
    Thomas, Vinay Mathew
    Li, Haoran
    Graf, Ryon P.
    Roy, Soumyajit
    Maughan, Benjamin L.
    Guha, Avirup
    Riaz, Irbaz Bin
    Antonarakis, Emmanuel S.
    Mckay, Rana R.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [36] Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel
    Ryan, Charles J.
    Dutta, Sandipan
    Kelly, William K.
    Middleberg, Rob
    Russell, Carly
    Morris, Michael J.
    Taplin, Mary-Ellen
    Halabi, Susan
    CLINICAL GENITOURINARY CANCER, 2020, 18 (03) : 222 - +
  • [37] Treatment patterns of new metastatic castration-resistant prostate cancer (mCRPC) therapies: Real-world evidence from three datasets.
    Ellis, Lorie
    Lafeuille, Marie-Helene
    Gozalo, Laurence
    Lefebvre, Patrick
    Malangone-Monaco, Elisabetta
    Wilson, Kathleen
    Foley, Kathleen A.
    McKenzie, R. Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [38] Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and tumors with androgen receptor (AR) 878/875 mutations
    Stewart, T. F.
    Gedrich, R.
    Saha, J.
    Chirnomas, D.
    Edwards, M.
    Lang, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1188 - S1188
  • [39] Real-world outcomes in second-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The Prostate Cancer Registry.
    Chowdhury, Simon
    Birtle, Alison J.
    Bjartell, Anders
    Costa, Luis
    Feyerabend, Susan
    Galli, Luca
    Kalinka-Warzocha, Ewa
    Kramer, Gero
    Lumen, Nicolaas
    Maroto, Pablo
    Matveev, Vsevolod B.
    Paiss, Thomas
    Pisconti, Salvatore
    Spaeth, Dominique
    Veiga, Francisco Gomez
    Antoni, Laurent
    Klumper, Edwin
    Wapenaar, Robert
    van den Berg, Erik
    Lee, Emma
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [40] Relationship of opioid analgesic (OA) use at 3 months and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Halabi, Susan
    Kelly, William Kevin
    Kaplan, Ellen B.
    Small, Eric Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
12345